neglect
tropic
diseas
ntd
affect
estim
billion
peopl
countri
develop
world
give
rise
myriad
advers
impact
includ
anemia
blind
cognit
impair
death
world
health
organ
prioritis
ntd
buruli
ulcer
chaga
diseas
cysticercosi
dengu
drancunculiasi
guinea
worm
diseas
echinococcosi
endem
treponematos
yaw
foodborn
trematod
infect
human
african
trypanosomiasi
hat
viscer
leishmaniasi
vl
leprosi
lymphat
filariasi
lf
onchocerciasi
rabi
schistosomiasi
soiltransmit
helminthias
sth
trachoma
control
elimin
ntd
select
basi
transmiss
characterist
treatment
opportun
make
good
candid
control
elimin
bill
melinda
gate
foundat
lead
pharmaceut
compani
meet
london
resolv
sustain
expand
extend
programm
ensur
necessari
suppli
drug
intervent
erad
guinea
worm
diseas
elimin
lf
leprosi
hat
blind
trachoma
control
schistosomiasi
sth
chaga
diseas
vl
onchocerciasi
london
declar
ensur
donat
drug
ntd
diagnost
critic
need
monitor
progress
toward
elimin
assess
impact
special
intervent
includ
declar
prioriti
defin
road
map
includ
five
key
intervent
help
countri
reach
goal
prevent
chemotherapi
base
largescal
use
safe
singledos
medicin
regular
interv
ie
mass
drug
administr
mda
ii
innov
intens
case
manag
iii
vector
ecolog
manag
iv
improv
water
sanit
hygien
ntdendem
area
v
veterinari
intervent
protect
improv
human
health
substanti
progress
made
last
decad
chemotherapi
reach
billion
peopl
said
diagnost
need
guid
chemotherapi
surveil
larg
due
perceiv
lack
commerci
viabl
market
ntd
diagnost
diagnost
need
except
guinea
worm
associ
unmistak
clinic
featur
monitor
certifi
elimin
ntd
dowdl
advoc
practic
diagnost
tool
suffici
sensit
specif
detect
level
infect
lead
transmiss
essenti
requir
diseas
elimin
erad
lack
clear
diagnost
strategi
result
limit
surveil
data
countri
often
use
use
diseas
burden
proxi
countrywid
data
solomon
et
al
suggest
countri
program
control
elimin
ntd
demand
improv
diagnost
tool
order
guid
decis
requir
intens
frequenc
durat
intervent
conduct
surveil
reemerg
infect
elimin
articl
examin
recent
advanc
diagnost
technolog
driven
high
profil
high
burden
diseas
hiv
tuberculosi
emerg
global
health
threat
antimicrobi
resist
emerg
outbreak
sar
ebola
viru
diseas
zika
viru
infect
determin
innov
leverag
improv
diagnosi
surveil
ntd
unaid
set
target
hiv
call
infect
know
hiv
statu
infect
put
treatment
treatment
achiev
viral
suppress
global
countri
respect
regard
target
realiz
target
good
perform
diagnost
monitor
test
wide
access
popul
remot
area
margin
care
need
diagnosi
tb
tradit
depend
smear
microscopi
chest
radiographi
insuffici
sensit
specif
cultur
highli
specif
requir
week
result
molecular
method
use
develop
countri
cost
requir
laboratori
infrastructur
skill
technic
staff
prevent
adopt
lowresourc
set
model
studi
show
test
sensit
specif
perform
singl
patient
visit
wide
implement
live
could
save
year
invest
pointofcar
poc
technolog
result
rang
highli
sensit
specif
hiv
tb
molecular
assay
perform
remot
set
test
design
samplein
answerout
format
requir
minim
train
provid
result
h
molecular
platform
detect
mycobacterium
tuberculosi
rifampicin
resist
high
accuraci
h
transform
tb
diagnosi
develop
develop
world
poc
test
enumer
commerci
avail
year
shorten
delay
hiv
treatment
poc
assay
hiv
earli
infant
diagnosi
viral
load
current
evalu
implement
shortli
expect
test
increas
access
hiv
viral
load
monitor
earli
infant
diagnosi
faster
turnaround
time
result
patient
increas
linkag
care
reduc
losstofollow
decreas
risk
drug
resist
invest
technolog
innov
driven
success
global
health
emerg
includ
sar
flu
mer
cov
ebola
viru
diseas
zika
viru
infect
call
develop
open
platform
technolog
acceler
develop
valid
product
vaccin
therapeut
diagnost
reagent
infecti
diseas
epidem
potenti
part
blue
print
r
prepared
minist
health
meet
consensu
financ
collabor
coordin
initi
blueprint
r
prepared
global
research
collabor
infecti
diseas
prepared
glopidr
prioriti
pathogen
blue
print
r
includ
crimean
congo
haemorrhag
fever
cchf
filovirus
lassa
sever
coronavirus
corona
virus
caus
sar
middl
east
respiratori
syndrom
mer
cov
nipah
viru
rift
valley
fever
chikungunya
zika
sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
infecti
diseas
caus
sft
viru
sftsv
novel
highli
pathogen
phleboviru
famili
bunyavirida
result
call
open
platform
technolog
industri
public
sector
develop
initi
collabor
work
togeth
acceler
product
develop
open
platform
technolog
develop
compani
alreadi
develop
highli
accur
poc
test
hiv
tb
mani
compani
also
develop
cartridg
detect
ebola
zika
virus
use
platform
compani
alreadi
develop
broad
menu
infecti
diseas
platform
advocaci
incent
advanc
market
commit
would
need
compani
appli
technolog
ntd
review
emerg
molecular
technolog
develop
use
resourcelimit
set
publish
antimicrobi
resist
amr
one
greatest
public
health
challeng
centuri
estim
death
billion
year
healthcar
expens
product
loss
europ
alon
unit
kingdom
amr
strategi
two
five
amr
target
requir
develop
diagnost
rapidli
identifi
infect
requir
antibiot
assay
use
identifi
track
pattern
antimicrobi
resist
rapid
poc
test
also
use
drug
trial
reduc
cost
length
trial
target
popul
identifi
recruit
without
expens
laboratori
test
procedur
diagnost
technolog
amr
current
avail
pipelin
describ
compendium
prepar
oxford
centr
evidencebas
medicin
challeng
creat
costeffect
accur
rapid
easytous
test
bacteri
infect
allow
health
profession
worldwid
administ
right
antibiot
right
time
rule
antibiot
use
identifi
viral
infect
number
initi
incentivis
public
privat
sector
develop
rapid
diagnost
test
assay
amr
surveil
announc
million
longitud
prize
prize
fund
diagnost
tool
use
rule
antibiot
use
help
identifi
effect
antibiot
treat
patient
horizon
prize
million
put
forth
european
commiss
incentivis
better
use
antibiot
respiratori
infect
develop
rapid
test
allow
healthcar
provid
distinguish
point
care
patient
respiratori
tract
infect
requir
antibiot
manag
safe
without
antibiot
us
nation
institut
health
also
offer
prize
million
first
group
develop
rapid
poc
diagnost
test
use
health
care
provid
identifi
highli
resist
bacteri
infect
promot
respons
use
antibiot
promis
high
throughput
array
technolog
pathogen
detect
coupl
detect
antimicrobi
suscept
pattern
amr
surveil
need
guid
patient
manag
improv
understand
emerg
spread
resist
ntd
commun
leverag
invest
diagnost
innov
improv
patient
manag
diseas
control
surveil
toward
elimin
ntd
differ
type
diagnost
need
inform
polici
decis
differ
stage
control
ntd
mda
main
control
strategi
multipl
round
mda
highli
sensit
specif
diagnost
need
locat
hot
spot
residu
infect
schistosomiasi
intens
transmiss
decreas
decreas
preval
infect
microscopi
longer
suffici
sensit
detect
residu
infect
commun
number
egg
per
gram
stool
fall
antigen
nucleic
acid
amplifi
test
naat
need
replac
microscopi
identifi
commun
transmiss
still
occur
howev
antigen
detect
test
use
enzym
immunoassay
later
flow
test
shown
suffici
sensit
current
naat
expens
technic
demand
commun
base
screen
naat
becom
avail
poc
format
data
transmiss
capabl
devic
taken
around
differ
commun
determin
stage
control
inform
treatment
strategi
much
progress
made
map
geograph
distribut
differ
ntd
area
overlap
ntd
sentinel
popul
similar
could
cost
save
effici
collect
singl
specimen
surveil
multipl
ntd
lf
trachoma
schistosomiasi
onchocerciasi
sentinel
popul
children
ten
year
age
multiplex
antibodi
detect
assay
perform
singl
dri
blood
spot
finger
prick
blood
offer
costeffect
mean
surveil
yaw
trachoma
requir
commun
base
treatment
one
round
mass
treatment
azithromycin
although
goal
yaw
trachoma
program
differ
implement
intervent
may
fulli
align
may
potenti
synergi
two
program
use
duplex
diagnost
test
case
find
surveil
diagnosi
viral
infect
tradit
made
demonstr
seroconvers
igm
rise
igg
titer
acut
convalesc
sera
taken
day
apart
pair
sera
difficult
obtain
hunsperg
et
al
show
recent
dengu
case
diagnos
singl
serum
specimen
collect
first
day
ill
test
either
denvrtpcr
igm
elisa
antigen
elisa
igm
elisa
open
excit
possibl
use
test
combin
diagnos
viral
ntd
singl
blood
sampl
taken
acut
phase
infect
offer
tremend
improv
current
struggl
global
health
emerg
caus
outbreak
viral
diseas
heymann
rodier
drew
attent
capabl
infecti
diseas
intellig
improv
earli
warn
capac
potenti
worldwid
public
health
problem
possibl
diminish
even
prevent
spread
infecti
diseas
connect
solut
test
pointofcar
use
provid
time
inform
test
trend
qualiti
assur
coupl
optim
suppli
chain
manag
alert
built
connect
system
support
diseas
surveil
outbreak
investig
nowaday
lot
poc
devic
digit
data
transmit
central
databas
integr
digit
technolog
diagnost
allow
ministri
health
uptothehour
inform
happen
across
countri
connect
solut
also
use
link
profici
test
result
test
site
alert
remedi
action
ultim
goal
improv
accuraci
test
across
countri
suppli
chain
manag
inform
link
test
databas
anoth
opportun
strengthen
healthcar
system
countri
bidirect
connect
allow
healthcar
site
send
inform
central
databas
databas
report
trend
back
site
oper
inform
devic
also
track
frequenc
devic
failur
error
rate
research
need
understand
middlewar
solut
whether
could
extract
set
data
differ
data
cloud
kind
knowledg
would
need
manag
system
field
advic
countri
would
need
human
resourc
train
would
make
health
system
lot
effici
inform
would
use
design
control
program
track
diseas
trend
assess
impact
intervent
real
time
poc
test
offer
rapid
identif
caus
infect
enabl
appropri
prescrib
take
test
outsid
laboratori
add
stress
weak
fragil
health
care
system
leadership
infrastructur
critic
decis
make
adopt
new
diagnost
technolog
often
fragment
absent
mani
countri
compani
novel
diagnost
technolog
often
face
long
delay
regulatori
approv
unnecessari
expenditur
associ
excess
duplic
clinic
trial
countri
intend
market
unlik
regul
adopt
new
drug
vaccin
global
govern
oversight
ensur
qualiti
effici
lack
diagnost
barrier
face
implement
test
pointofcar
often
technolog
constraint
inher
health
care
system
implement
success
poc
diagnost
programm
engag
polici
maker
stakehold
partner
ensur
buyin
align
necessari
resourc
critic
first
step
train
certif
vast
number
health
care
provid
use
poc
diagnost
ensur
effect
suppli
chain
test
drug
across
countri
present
enorm
challeng
health
system
alreadi
suffer
critic
shortag
human
resourc
qualiti
assur
system
includ
provid
profici
test
site
visit
correct
action
essenti
ensur
accur
result
use
guid
treatment
decis
ensur
control
strategi
base
accur
surveil
data
studi
shown
deploy
poc
diagnost
opportun
improv
health
outcom
strengthen
health
system
overcom
challeng
turn
motiv
health
care
worker
increas
capac
effici
test
treat
appropri
rdt
introduct
implement
must
cultur
sensit
accompani
interconnect
system
monitor
necessari
process
anoth
key
barrier
appropri
use
poc
diagnost
need
train
clinician
creat
demand
use
test
result
effect
manag
patient
improv
laboratoryclinician
interfac
import
often
neglect
aspect
test
introduct
appropri
diagnost
monitor
diseas
trend
assess
impact
intervent
essenti
guid
treatment
strategi
ntd
differ
threshold
control
interrupt
transmiss
elimin
postelimin
surveil
new
sampl
inansw
nucleic
acid
amplif
technolog
offer
improv
perform
antigen
detect
poct
potenti
test
multipl
pathogen
use
singl
specimen
recent
technic
advanc
led
improv
diagnost
test
ntd
sensit
specif
abl
diagnos
multipl
infect
use
singl
specimen
use
point
care
sinc
extens
geograph
overlap
differ
ntd
target
mda
multiplex
surveil
platform
like
prove
costeffect
rapid
deploy
new
technolog
control
elimin
ntd
present
multipl
challeng
fragil
health
system
includ
qualiti
assur
stockout
suppli
need
test
treatment
connect
solut
link
data
diagnost
laboratori
poc
test
readersdevic
provid
opportun
autom
surveil
system
make
health
system
effici
improv
patient
outcom
assess
impact
intervent
real
time
new
model
product
develop
partnership
critic
leverag
diagnost
innov
prioriti
area
better
diagnosi
control
elimin
ntd
